Necrotizing pancreatitis and antibiotic prophylaxis. To use or not to use ... that is the question.
Avard
Bronwyn
B
Fergusson
James
J
D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D019072:Antibiotic Prophylaxis / Q000009:adverse effects; D002097:C-Reactive Protein / Q000378:metabolism; D015377:Cilastatin / Q000008:administration & dosage; D000077728:Cilastatin, Imipenem Drug Combination; D018450:Disease Progression; D004338:Drug Combinations; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage; D009181:Mycoses / Q000139:chemically induced; D010179:Pancreas / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000601:surgery; D010180:Pancreatectomy; D010195:Pancreatitis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D019283:Pancreatitis, Acute Necrotizing / Q000000981:diagnostic imaging / Q000209:etiology / Q000473:pathology / Q000517:prevention & control* / Q000601:surgery; D018579:Patient Selection; D012720:Severity of Illness Index; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D015377:Cilastatin; D015378:Imipenem; D002097:C-Reactive Protein; D000077728:Cilastatin, Imipenem Drug Combination